BMS Announces Latest Data on Lung Cancer with Immune Combination Therapy Opdivo+Yervoy

Recently, Bristol-Myers Squibb (BMS) announced the 3-year follow-up results of the phase 3 CheckMate-9LA trial of the immunocombination therapy Opdivo+Yervoy in the first-line treatment of lung cancer and the 5-year follow-up results of the first part of the phase 3 CheckMate-227 tri.

3-year follow-up results from the phase 3 CheckMate-9LA trial showed the immunocombination therapy Opdivo+Yervoy 2 compared with 4 cycles of chemotherapy in patients with previously untreated metastatic non-small cell lung cancer (mNSCLC) 1 cycle of chemotherapy showed durable survival benef.

In addition, long-lasting clinical benefit was also observed with combination therapy compared with chemotherapy after 3 years in a patient population with a generally poor prognosis, including patients with PD-L1 expression <1% (3-year OS rate: 25% vs 15.

5-year follow-up results from the first part of the phase 3 CheckMate-227 trial showed a long-term, durable survival benefit with Opdivo+Yervoy as first-line therapy compared with chemotherapy in previously untreated patients with mNSCLC, regardless of PD-L1 expression How is the lev.

Minimum follow-up of 5 years (63 months):

Among patients with tumor PD-L1 expression ≥1%, the 5-year survival rate was 24% in the Opdivo+Yervoy group and 14% in the chemotherapy group (HR=77; 95%CI: 66-9

Among patients with PD-L1 <1%, the 5-year survival rate in the Opdivo+Yervoy group was almost 3 times that in the chemotherapy group (19% vs 7%; HR = 65; 95% CI: 52-8

In the treatment-responsive patient population, more patients in the Opdivo+Yervoy group were still in remission after 5 years (3+ years off treatment, up to 2 years end of immunotherapy by protocol), including PD-L1 ≥ 1% of the patient population (28% vs 3%) and PD-L1 <1% of the patient population (21% vs 0.

About two-thirds (66%) of patients treated with Opdivo+Yervoy who were alive after 5 years (66% PD-L1 expression ≥1%, 64% PD-L1 expression <1%) stopped treatment No follow-up treatment was received for more than 3 yea.

Without treatment, mNSCLC has a very poor prognosis, with a 5-year survival rate of about

In addition to first-line mNSCLC, Bristol-Myers Squibb also announced post-hoc analysis data from the Phase 3 CheckMate-816 trial of Opdivo combined with chemotherapy in neoadjuvant (preoperative) treatment of early-stage lung canc.

The latest post-hoc analysis data from Bristol-Myers Squibb supports the link in the treatment of early-stage NSC.